Insight Molecular Diagnostics Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY
| Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Income | Deficit | Deficit | |
| Balance at March 31, 2026 | 32,286 | $394,289 | $71 | $(405,051) | $(10,691) |
| Net Loss | — | — | — | (11,260) | (11,260) |
| Foreign currency translation adjustment | — | — | (4) | — | (4) |
| Stock-based compensation | — | 661 | — | — | 661 |
| Stock options exercised | 4 | 10 | — | — | 10 |
| Shares issued upon vesting of RSUs | 12 | — | — | — | — |
| Shares issued for consultant services | 2 | 8 | — | — | 8 |
| Shares withheld related to net share settlement of stock-based awards | (4) | (23) | — | — | (23) |
| Issuance of common stock upon exercise of pre-funded warrants | 323 | — | — | — | — |
| Balance at June 30, 2026 | 32,623 | $394,945 | $67 | $(416,311) | $(21,299) |
| Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Income | Deficit | Equity | |
| Balance at March 31, 2025 | 28,599 | $367,387 | $41 | $(357,210) | $10,218 |
| Net Loss | — | — | — | (9,742) | (9,742) |
| Foreign currency translation adjustment | — | — | 44 | — | 44 |
| Stock-based compensation | — | 504 | — | — | 504 |
| Vesting of bonus awards | — | 14 | — | — | 14 |
| Shares issued for consultant services | 18 | 60 | — | — | 60 |
| Balance at June 30, 2025 | 28,617 | $367,965 | $85 | $(366,952) | $1,098 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ (DEFICIT) EQUITY
| Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Income | Deficit | Deficit | |
| Balance at December 31, 2025 | 28,683 | $369,211 | $86 | $(400,761) | $(31,464) |
| Net Loss | — | — | — | (15,550) | (15,550) |
| Foreign currency translation adjustment | — | — | (19) | — | (19) |
| Stock-based compensation | — | 1,276 | — | — | 1,276 |
| Vesting of bonus awards | — | 8 | — | — | 8 |
| Sale of common shares, net of financing costs | 3,482 | 24,645 | — | — | 24,645 |
| Stock options exercised | 4 | 10 | — | — | 10 |
| Shares issued upon vesting of RSUs | 180 | — | — | — | — |
| Shares issued for consultant services | 7 | 32 | — | — | 32 |
| Shares withheld related to net share settlement of stock-based awards | (56) | (237) | — | — | (237) |
| Issuance of common stock upon exercise of pre-funded warrants | 323 | — | — | — | — |
| Balance at June 30, 2026 | 32,623 | $394,945 | $67 | $(416,311) | $(21,299) |
| Common Stock · AccumulatedOtherComprehensive · Accumulated · TotalShareholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Income | Deficit | (Deficit) Equity | |
| Balance at December 31, 2024 | 17,453 | $338,244 | $21 | $(350,539) | $(12,274) |
| Net loss | — | — | — | (16,413) | (16,413) |
| Foreign currency translation adjustment | — | — | 64 | — | 64 |
| Stock-based compensation | — | 977 | — | — | 977 |
| Vesting of bonus awards | — | 28 | — | — | 28 |
| Sale of common shares, net of financing costs | 11,146 | 28,656 | — | — | 28,656 |
| Shares issued for consultant services | 18 | 60 | — | — | 60 |
| Balance at June 30, 2025 | 28,617 | $367,965 | $85 | $(366,952) | $1,098 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.